Carregant...
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it led to up to 60% response rates, making it, nearly 20 years ago, the main alternative to splenectomy, with far fewer side effects. However, long-term follow-up data showed that only 20-30% of patients...
Guardat en:
| Publicat a: | Haematologica |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Ferrata Storti Foundation
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6545833/ https://ncbi.nlm.nih.gov/pubmed/31126963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.218883 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|